内科理论与实践

内科理论与实践 >

2025 , Vol. 20 >Issue 02: 178 - 182

DOI: https://doi.org/10.16138/j.1673-6087.2025.02.14

综述

相关标志物及肠道微生物对结直肠癌肝转移的研究进展

  • 弓殷 ,
  • 王学玲
展开
  • 1.山西医科大学汾阳学院，山西 汾阳 032200
    2.山西医科大学附属汾阳医院消化内科，山西 汾阳 032200
王学玲 E-mail:wangxueling2315@163.com

收稿日期: 2024-07-03

  网络出版日期: 2025-07-08

收起

Research progress on related markers and intestinal microorganisms in colorectal cancer liver metastasis

  • GONG Yin ,
  • WANG Xueling
Expand
  • 1. Fenyang College Shanxi Medical University, Fenyang 032200, China
    2. Department of Gastroenterology,Fenyang Hospital, Shanxi Medical University, Fenyang 032200, China

Received date: 2024-07-03

  Online published: 2025-07-08

Fold

摘要

结直肠癌（colorectal cancer,CRC）是消化道常见的恶性肿瘤之一，其肝转移是导致患者死亡的主要原因。肝转移患者早期缺乏典型临床症状，现有影像学方法检出率有限，生物标志物的研究对于预测治疗反应、监测疾病进展及制定个性化治疗方案至关重要。近年，CRC肝转移标志物的研究取得显著进展，为达到早发现、早诊断、早治疗的目的，本文总结既往研究中与CRC肝转移相关的各类生物标志物，旨在探讨其在CRC肝转移早期诊断中的应用价值，以期为临床实践提供参考

关键词： 结直肠癌; 肝转移; 生物标志物

本文引用格式

弓殷 , 王学玲 . 相关标志物及肠道微生物对结直肠癌肝转移的研究进展[J]. 内科理论与实践, 2025 , 20(02) : 178 -182 . DOI: 10.16138/j.1673-6087.2025.02.14

Abstract

Colorectal cancer (CRC) is one of the common malignant tumors in the digestive tract, and its liver metastasis is the main cause of death for patients. Due to the lack of typical clinical symptoms in patients with liver metastasis in the early stage, the study of biomarkers is crucial for predicting treatment response, monitoring disease progression, and formulating personalized treatment plans. In recent years, significant progress has been made in the research of CRC liver metastasis biomarkers to achieve the goals of early detection, early diagnosis and early treatment. This article summarizes various biomarkers related to CRC liver metastasis in previous studies, aiming to explore their application value in the early diagnosis of CRC liver metastasis, in order to provide a reference for clinical practice.

Key words： Colorectal cancer; Hepatic metastases; Biomarker

参考文献

[1] 田一禾, 刘宏, 白亮彩. 结直肠癌肝转移的影像学评估研究进展[J]. 磁共振成像, 2023, 14(2): 191-196.
[2] Xu R, Chi H, Zhang Q, et al. Enhancing the diagnostic accuracy of colorectal cancer through the integration of serum tumor markers and hematological indicators with machine learning algorithms[J]. Clin Transl Oncol, 2025, 27(1): 299-308.
[3] You W, Yan L, Cai Z, et al. Clinical significances of positive postoperative serum CEA and post-preoperative CEA Increment in stage Ⅱ and Ⅲ colorectal cancer: a multicenter retrospective study[J]. Front Oncol, 2020, 10: 671.
[4] 郭鹏伟, 赵红梅, 王毅, 等. 晚期结直肠癌患者靶向治疗前后血清CEA、CA125、CA199变化及与疗效的关系[J]. 河北医药, 2024, 46(12): 1849-1852
[5] 曾艳, 张力, 贺帅. 结直肠癌患者血清CEA和CA19-9水平与肝转移的关系[J]. 癌症进展, 2019, 17(13): 1586-1589.
[6] 张晓斌. 血常规、血生化联合血清CEA、CA19-9在结直肠癌肝转移诊断中的应用价值[J]. 现代医学与健康研究电子杂志, 2020, 4(17): 100-102.
[7] 左壮, 张银旭, 徐宇. SII、TAP、CEA及CA19-9与CRC肝转移的关系[J]. 江苏医药, 2023, 49(12): 1243-1246.
[8] Wang K, Zheng J, Yu J, et al. Knockdown of MMP?1 inhibits the progression of colorectal cancer by suppressing the PI3K/Akt/c?myc signaling pathway and EMT[J]. Oncol Rep, 2020, 43(4): 1103-1112.
[9] 王鑫, 王钊, 李元春, 等. 热休克蛋白70及基质金属蛋白酶-7和EHD2蛋白在结直肠癌组织中的表达及意义[J]. 新乡医学院学报, 2019, 36(5): 443-447.
[10] 蒋炳林, 何永亮, 陈开蓉. MMP3、THBS2、COL10A1和miR-1229对早期结直肠癌的诊断价值[J]. 标记免疫分析与临床, 2019, 26(6): 994-999.
[11] 李紫云. MMP-28在结直肠癌中的表达及以意义[D]. 石家庄: 河北医科大学, 2023.
[12] 徐辉, 唐言华, 刘继武, 等. 基质金属蛋白酶2、整合素-金属蛋白酶17及上皮性钙粘附蛋白E在CRC癌组织中的表达及临床意义[J]. 实用医学杂志, 2021, 37(2): 220-225.
[13] Marisi G, Azzali I, Passardi A, et al. Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer[J]. Sci Rep, 2023, 13(1): 12921.
[14] Inanc M, Sirakaya HA, Karaman H, et al. The prognostic importance of VEGF-A, PDGF-BB and c-MET in patients with metastatic colorectal cancer[J]. J Oncol Pharm Pract, 2020, 26(8): 1878-1885.
[15] 顾玉兰, 丘佳明, 蒋廷旺, 等. 结直肠癌中VEGF-C和MMP-2蛋白表达量与肿瘤侵袭转移关系的研究[J]. 现代肿瘤医学, 2019, 27(9): 1576-1580.
[16] Paget S. The distribution of secondary growths in cancer of the breast. 1889[J]. Cancer Metastasis Rev, 1989, 8(2): 98-101.
[17] Arrazubi V, Mata E, Antelo ML, et al. Circulating tumor cells in patients undergoing resection of colorectal cancer liver metastases. Clinical utility for long-term outcome: a prospective trial[J]. Ann Surg Oncol, 2019, 26(9): 2805-2811.
[18] 李茉. 基于ROS介导JNK/p38 MAPK的激活对人参皂苷Rg5促进人肺腺癌凋亡及细胞周期阻滞的机制研究[D]. 长春: 吉林大学, 2023.
[19] 邱芬, 郗雪艳, 杜伯雨. 白血病抑制因子通过调控CD44的表达增强结直肠癌细胞干性特征[J]. 中国病理生理杂志, 2024, 40(10): 1826-1833.
[20] 王宜珂. 转录组学分析MACC1与结直肠癌转移的关系[D]. 新乡: 新乡医学院, 2023.
[21] Zahran AM, Amal Rayan, Fakhry H, et al. Pretreatment detection of circulating and tissue CD133+ CD44+ cancer stem cells as a prognostic factor affecting the outcomes in Egyptian patients with colorectal cancer[J]. Cancer Manag Res, 2019, 11: 1237-1248.
[22] Peng H, Ye T, Deng L, et al. Activin and hepatocyte growth factor promotes colorectal cancer stemness and metastasis through FOXM1/SOX2/CXCR4 signaling[J]. Gut Liver, 2024, 18(3): 476-448.
[23] Zhao C, Gan C, Xiao Y, et al. High expression of long non-coding RNA linc-A associates with poor survival in patients with colorectal cancer[J]. Mol Biol Rep, 2020, 47(10): 7497-7504.
[24] 王广月, 周林妍. 结直肠癌组织中METTL3、miR-23a-3p表达与病理参数及术后肝转移的关系[J]. 新疆医科大学学报, 2024, 47(5): 729-733.
[25] 徐咏强, 叶伟标, 陈靖, 等. 血清circFAT1在结直肠癌肝转移中的预测价值[J]. 系统医学, 2020, 5(12): 24-26.
[26] 杨大计. MiR-4461调控肝癌干细胞恶性表型抑制肝癌耐药的机制及其临床相关性研究[D]. 长春: 吉林大学, 2023.
[27] 李青, 崔发财, 杨红杰, 等. lncRNA LINC00460在结直肠癌组织中的表达及其对细胞增殖、侵袭和迁移能力的影响[J]. 现代肿瘤医学, 2023, 31(18): 3405-3411.
[28] Liu S, Cao Q, An G, et al. Identification of the 3-lncRNA signature as a prognostic biomarker for colorectal cancer[J]. Int J Mol Sci, 2020, 21(24): 9359.
[29] Lu X, Xu Q, Tong Y, et al. Long non-coding RNA EVADR induced by fusobacterium nucleatum infection promotes colorectal cancer metastasis[J]. Cell Rep, 2022, 40(3): 111127.
[30] Jin L, Li C, Liu T, et al. A potential prognostic prediction model of colon adenocarcinoma with recurrence based on prognostic lncRNA signatures[J]. Hum Genomics, 2020, 14(1): 24.
[31] 陈超, 徐俊, 李幸, 等. 结肠癌组织中lncRNA HOXA-AS3、miR-29b表达变化及意义[J]. 山东医药, 2023, 63(19): 50-53.
[32] Guan RJ, Ford HL, Fu Y, et al. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer[J]. Cancer Res, 2020, 60(3): 749-755.
[33] 张云鹏. 基于蛋白质组学的结直肠癌发生和发展的多水平研究[D]. 上海: 华东师范大学, 2023.
[34] 张翔, 蒋微琴, 华汉巨, 等. Ⅰ-Ⅲ期MSS型结直肠癌患者RAS/BRAF基因不同密码子突变的临床病理特征、转移部位及临床预后比较[J]. 中国普外基础与临床杂志, 2024, 31(6): 682-689.
[35] Granata V, Fusco R, Risi C, et al. Diffusion-weighted MRI and diffusion kurtosis imaging to detect RAS mutation in colorectal liver metastasis[J]. Cancers (Basel), 2020, 12(9): 2420.
[36] Petrelli F, Arru M, Colombo S, et al. BRAF mutations and survival with surgery for colorectal liver metastases: a systematic review and meta-analysis[J]. Eur J Surg Oncol, 2024, 50(6): 108306.
[37] Xu M, Wang Y, Xia R, et al. Role of the CCL2-CCR2 signalling axis in cancer: mechanisms and therapeutic targeting[J]. Cell Prolif, 2021, 54(10): e13115.
[38] Fei L, Ren X, Yu H, et al. Targeting the CCL2/CCR2 axis in cancer immunotherapy: one stone, three birds?[J]. Front Immunol, 2021, 12: 771210.
[39] Xu C, Fan L, Lin Y, et al. Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization[J]. Gut Microbes, 2021, 13(1): 1980347.
[40] Bi F, Wang Q, Dong Q, et al. Circulating tumor DNA in colorectal cancer: opportunities and challenges[J]. Am J Transl Res, 2020, 12(3): 1044-1055.
[41] Mo S, Ye L, Wang D, et al. Early detection of molecular residual disease and risk stratification for stage ⅠtoⅢ colorectal cancer via circulating tumor DNA methylation[J]. JAMA Oncol, 2023, 9(6): 770-778.
[42] 王真, 刘燕文. ctDNA在可切除结直肠癌肝转移中的应用[J]. 东南大学学报(医学版), 2020, 39(4): 509-513.
[43] Luo H, Zhao Q, Wei W, et al. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer[J]. Sci Transl Med, 2020, 12(524): eaax7533.
[44] Koyande N, Gangopadhyay M, Thatikonda S, et al. The role of gut microbiota in the development of colorectal cancer: a review[J]. Int J Colorectal Dis, 2022, 37(7): 1509-1523.
[45] Fan X, Jin Y, Chen G, et al. Gut Microbiota dysbiosis drives the development of colorectal cancer[J]. Digestion, 2021, 102(4): 508-515.
[46] Kim J, Lee HK. Potential role of the gut microbiome in colorectal cancer progression[J]. Front Immunol, 2022, 12: 807648.
[47] Rossi T, Vergara D, Fanini F, et al. Microbiota-derived metabolites in tumor progression and metastasis[J]. Int J Mol Sci, 2020, 21(16): 5786.
[48] Yu J, Feng Q, Wong SH, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer[J]. Gut, 2017, 66(1): 70-78.
[49] 樊启林, 张松, 徐丹, 等. 结直肠癌肝转移和非肝转移患者的肠道菌群构成差异[J]. 实用肿瘤杂志, 2023, 38(3): 229-238.
[50] Uchino Y, Goto Y, Konishi Y, et al. Colorectal cancer patients have four specific bacterial species in oral and gut microbiota in common-a metagenomic comparison with healthy subjects[J]. Cancers, 2021, 13(13): 3332.
[51] Chen S, Su T, Zhang Y, et al. Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7-AS/KRT7[J]. Gut Microbes, 2020, 11(3): 511-525.
Options
文章导航

/

〈 〉